| 发明名称 | Proteostasis regulators | ||
| 摘要 | The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds. | ||
| 申请公布号 | US9556166(B2) | 申请公布日期 | 2017.01.31 |
| 申请号 | US201213468757 | 申请日期 | 2012.05.10 |
| 申请人 | Proteostasis Therapeutics, Inc. | 发明人 | Foley Megan;Tait Bradley;Cullen Matthew |
| 分类号 | C07D401/06;C07D403/06;C07D405/06;C07D471/04;C07D207/333;C07D207/337;C07D231/12;C07D249/06;C07D263/32;C07D275/02;C07D295/185;C07D333/20 | 主分类号 | C07D401/06 |
| 代理机构 | Elmore Patent Law Group, P.C. | 代理人 | Elmore Patent Law Group, P.C. ;Hoda Mahreen Chaudhry;Elmore, Esq. Carolyn S. |
| 主权项 | 1. A compound having the Formula (II): or a pharmaceutically acceptable salt, or solvate thereof, wherein: D is optionally substituted phenyl; Q is C(Rd); each Ri is independently selected from the group consisting of hydrogen and optionally substituted C1-C10 alkyl; R5 and R6 are each independently selected from the group consisting of hydrogen and optionally substituted C1-C10 alkyl; Z1 is NRcRc; each Rc is independently selected from the group consisting of hydrogen and optionally substituted C1-C10 alkyl; or alternatively, the two Rc groups are taken together with the nitrogen atom to which they are attached to form an optionally substituted 3- to 8-membered heterocyclic; and Rd is optionally substituted C1-C10 alkyl. | ||
| 地址 | Cambridge MA US | ||